WDNA
WisdomTree BioRevolution Fund
WDNA tracks a modified equally-weighted index of companies in developed markets that focus on the advancements in genetics and biotechnology.
International
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 2.3 M
ASSETS UNDER MGMT
45 bp
EXPENSES
Fund Basics
| Inception date | Jun 03, 2021 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Annually |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
| EXACT SCIENCES CORP | 28.0 % |
| MODERNA, INC. | 4.3 % |
| JOHNSON & JOHNSON | 3.0 % |
| STRUCTURE THERAPEUTICS INC ADR | 2.6 % |
| PFIZER INC | 2.5 % |
| STOKE THERAPEUTICS, INC. | 2.5 % |
| ELI LILLY & CO | 2.4 % |
| UNITED THERAPEUTICS CORP | 2.4 % |
| AMGEN INC | 2.3 % |
| NATERA INC | 2.2 % |
Constituent Breakdown
| Number of holdings | 85 |
| Herfindahl-Hirschman Index | 935 |
| Wgt avg mkt cap (mns) | $83,398 |
| Large cap (>$10bn) | 50.2% |
| Mid cap ($2-10bn) | 18.8% |
| Small cap (<$2bn) | 21.7% |
| Developed mkts. | 117.1% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 97.8 % |
 |
DENMARK | 4.8 % |
 |
BRITAIN | 4.0 % |
 |
GERMANY | 3.8 % |
 |
SWITZERLAND | 3.3 % |
 |
NETHERLANDS | 1.5 % |
 |
JAPAN | 1.2 % |
 |
BELGIUM | 0.5 % |
Historical Performance
Standardized Performance (as of 04/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 5.6% | 34.4% | 7.8% | 1.4% | -- | -- | -- | -6.6% |
| Dividend Yield | 0.0% | 0.0% | 0.4% | 0.5% | -- | -- | -- | 0.4% |
| Total Returns | 5.6% | 34.4% | 8.2% | 1.9% | -- | -- | -- | -6.3% | Ann. Volatility | 24.5% | 27.4% | 25.9% | 25.2% | -- | -- | -- | 25.2% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 1.19 | 29% |
| MSCI EAFE | 0.98 | 27% |
| MSCI Emg Mkts | 0.65 | 19% |
Liquidity Measures
| Avg. volume (000) | 1 |
| ADV traded (mns) | $0 |
| Turnover | 0.8% |
| Avg. Bid/Ask (% of price) | 0.93% |
Technical Indicators
| 30d moving avg. (EMA) | $17.81 |
| Relative strength (RSI) | 51 |
| MACD/Signal | 0.03/0.10 |
| Bollinger Bands (Upper/Lower) | $18.70/$17.29 |
| Short interest (% of AUM) | 0.3% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. WDNA |
Expenses vs. WDNA |
ALTAR Score™ vs. WDNA |
|---|---|---|---|---|
| GNOM | Global X Genomics & Biotechnology ETF | 33.1% | +5 bp | -0.3% |
| XBI | State Street SPDR S&P Biotech ETF | 29.5% | -10 bp | +3.0% |
| IBB | iShares Biotechnology ETF | 29.0% | 0 bp | +2.4% |
| BMED | Future Health ETF | 27.5% | +40 bp | +4.0% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 26.8% | +15 bp | +10.7% |
| HELX | Franklin Genomic Advancements ETF | 26.7% | +5 bp | +2.0% |
| BBP | Virtus LifeSci Biotech Products ETF | 26.7% | +34 bp | -0.8% |
| HRTS | Tema Heart & Health ETF | 25.6% | +30 bp | +6.3% |
| IXJ | iShares Global Healthcare ETF | 24.6% | -3 bp | +10.0% |
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 23.5% | +11 bp | +5.0% |
Risk and Returns: WDNA vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 5/3/2026
Peer Group Comparison Sample data. Subscribe for access.
Price-to-Earnings
Price-to-Sales
Price-to-Book Value
Price-to-Cash Flow
Price-to-Growth
Dividend Yield
Historical Valuation Trends Sample data. Subscribe for access.
SHOWING:
Price-to-Earnings
Price-to-Earnings
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
-3.0%
ALTAR SCORE™
1st
PERCENTILE
AVOID
ETFRC RATING
There are 327 funds in the International Equity category with an average
ALTAR Score™ of 6.3% and a standard deviation
of 1.6%. WDNA's ALTAR Score™ is approximately -6.0 standard
deviations above the category average. This places WDNA in the 1st percentile
among funds in the category.
Sell-Side Consensus
$21.52
PRICE TARGET
+20.4%
UPSIDE